First-in-human study of EP102 in advanced solid tumors initiated
The first-in-human study for EP102 aims to evaluate safety, tolerability, and antitumor activity in advanced solid tumors.
Phase III
Oncology / Solid Tumors
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the first-in-human study for EP102 represents a significant step in the oncology pipeline, particularly in a therapeutic area with limited options. Positive outcomes could enhance competitive positioning and inform future development strategies in oncology.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the announcement of maximum tolerated dose and preliminary efficacy results.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.